Table 2.
Post-lapse Analysis
| Factor | Overall (N = 164) |
Control Group (n = 82) | Lapse Group (n = 82) | P Value | |
|---|---|---|---|---|---|
| n | Statistics | ||||
| ETDRS | 164 | 67.7 ± 14.4 | 68.9 ± 14.5 | 66.5 ± 14.3 | .136a |
| CST (μm) | 158 | 347.5 ± 102.0 | 335.4 ± 94.6 | 359.9 ± 108.3 | .066a |
| CV (mm3) | 158 | 11.3 ± 1.7 | 11.0 ± 1.4 | 11.6 ± 2.0 | .029a |
| CAT (μm) | 158 | 314.2 ± 47.2 | 307.0 ± 39.6 | 321.6 ± 53.1 | .034a |
| Anti-VEGF drug, n (%) | 164 | .99b | |||
| Bevacizumab | 56 (34.1) | 28 (34.1) | 28 (34.1) | ||
| Aflibercept | 22 (13.4) | 11 (13.4) | 11 (13.4) | ||
| Ranibizumab | 18 (11.0) | 9 (11.0) | 9 (11.0) | ||
| No injection | 64 (39.0) | 32 (39.0) | 32 (39.0) | ||
| Otherc | 4 (2.4) | 2 (2.4) | 2 (2.4) | ||
| Lapse length, n (%) | 164 | — | |||
| <6 mo | 135 (82.3) | – | 53 (64.6) | ||
| >6 mo | 29 (17.7) | – | 29 (35.4) | ||
| CST change baseline to postlapse, n (%) | 149 | <.001b | |||
| ≤20 | 94 (63.1) | 59 (75.6) | 35 (49.3) | ||
| >20 | 55 (36.9) | 19 (24.4) | 36 (50.7) | ||
CAT = cube average thickness; CST = central subfield thickness; CV = cube volume; ETDRS = Early Treatment Diabetic Retinopathy Study; VEGF = vascular endothelial growth factor.
Subset of population used: Appointment = “First.” Unless otherwise noted, values are mean ± SD.
Bold represents statistically significant values.
a
Paired t test.
b
McNemar test.
c
Other indicates that the patient received a corticosteroid injection at the given appointment rather than anti-VEGF.